Ponatinib
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
Product Specifications
CAS Number
943319-70-8
Product Name Alternative
AP24534
UNSPSC
12352005
Hazard Statement
H301, H311, H315, H319, H331, H335
Target
Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Ponatinib.html
Purity
99.67
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=C(C=C(C=C1)C(NC2=CC(C(F)(F)F)=C(C=C2)CN3CCN(CC3)C)=O)C#CC4=CN=C5N4N=CC=C5
Molecular Formula
C29H27F3N6O
Molecular Weight
532.56
Precautions
H301, H311, H315, H319, H331, H335
References & Citations
[1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16 (5), 401-412.|[2]Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther, 2011, 10 (6), 1028-1035.|[3]Uchida T, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014 May;42 (5) :369-379.e3.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDGFRα; VEGFR2/KDR/Flk-1
Citation 01
Acta Pharm Sin B. 2023 Oct;13 (10) :4253-4272.|Acta Pharmacol Sin. 2021 Jan;42 (1) :108-114.|Biochem Pharmacol. 2021 Oct:192:114710.|Biomed Pharmacother. 2024 Nov:180:117569.|Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomolecules. 2022 Jun 11;12 (6) :819.|bioRxiv. 2024 Apr 21.|bioRxiv. 2025 February 26.|bioRxiv. 2025 May 5:2025.04.30.651490.|bioRxiv. 2025 Sep 30.|Blood Vessel Thromb Hemost. 2025 Nov 17.|BMC Chem. 2025 Aug 22;19 (1) :248.|Cancer Discov. 2021 Jan;11 (1) :126-141.|Cancer Sci. 2025 Apr;116 (4) :1115-1125.|Cell Rep Med. 2025 Apr 2:102053.|Clin Chim Acta. 2018 May:480:180-185.|Commun Biol. 2024 Jul 10;7 (1) :843.|Eur J Pharmacol. 2020 Dec 15;889:173292.|Exp Hematol. 2014 May;42 (5) :369-379.e3.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Heliyon. 2024 Sep 28;10 (19) :e38637.|Int J Biol Macromol. 2024 Dec 2:138305.|J Chem Eng Data. 2024 Jun 10.|J Ethnopharmacol. 2023 Jun 12:309:116275.|J Ethnopharmacol. 2024 Apr 6:323:117669.|J Ethnopharmacol. 2025 Sep 17;355 (Pt A) :120621.|J Hypertens. 2025 May 1;43 (5) :827-840.|J Inflamm Res. 2025 Jun 26:18:8447-8475.|J Med Chem. 2019 May 23;62 (10) :5006-5024. |J Med Chem. 2024 Nov 28;67 (22) :20571-20579.|Leuk Res. 2016 Jun:45:24-32.|Neurosci Bull. 2020 Mar;36 (3) :263-276.|Pharmaceuticals (Basel) . 2022 Aug 29;15 (9) :1073.|Pharmacogn Mag. 2023 Jul 20.|PLoS One. 2021 Sep 30;16 (9) :e0258140.|PLoS One. 2022 Feb 14;17 (2) :e0263822.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Preprint. 2021 May.|Research Square Print. 2023 Mar 23.|Sci Rep. 2025 Jul 2;15 (1) :22961.|Sci Rep. 2025 Oct 16;15 (1) :36227.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Target Oncol. 2020 Oct;15 (5) :659-671.|Technical University of Munich. 24.01.2018.|University of Pittsburgh. 2025.|Biomaterials. 2022 Oct:289:121800.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LC402042 20 µg
EBNA1 binding protein 2 (EBNA1BP2) (NM_006824) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC400498-500 1x 500 µL
PAX6 (PAX6/498), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details